IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
• Year: 2007
No vem ber: Takeda has es tab lished a new com pany ‘Takdea San Fran cisco, Inc’ (TSF) for ther a peu tic an -
ti body re search. This is part of Takeda’s 2006-10 ‘Me dium Term Plan’ to en hance de vel op ment ca pa bil i -
ties to cre ate new drugs in-house.
Feb ru ary: QLT (USA) signed an agree ment with TAP Pharmaceuticals set tling the US pat ent lit i ga tion, ini -
ti ated in 2003 claim ing that Atrix’s (now QLT’s) Eligard prod ucts in fringed a pat ent. QLT is to pay 4112.5
mil lion and Sanofi-Aventis will pay 445 mil lion to Tap who will re lease claims made in the US lit i ga tion
against the companies.
Jan u ary: Takeda has sub mit ted a plan for a new re search fa cil ity to be built in the city of Fujisawa, an ap -
proval is an tic i pated in April 2007. Takeda is also to in te grate its re search cen ters in Osaka and Tsukuba
to im prove com mu ni ca tion and co-or di na tion. The new fa cil ity to gether with the San Diego re search cen -
ter will form the core of Takeda’s global re search ca pa bil ity. Re search pri or i ties at the new cen ter in clude
can cer, CNS and life style re lated dis eases; op er a tions are ex pected to be gin in fis cal 2010 by which point
Yen70 bil lion will be in vested and more per son nel will be added to the current 1,000 researchers
employed.
Takeda plans to cen tral ize fund man age ment of its Eu ro pean sub sid iar ies through the trans fer of com -
pany owned shares to Takeda Eu rope Hold ings. The move aims to cen tral ize ad min is tra tion of Takeda’s
op er at ing fund and en hance its presence in Europe.
• Year: 2006
Takeda an nounced that Mr Giacomo Di Nepi was to be the CEO of a newly-cre ated Eu ro pean com pany,
Takeda Pharmaceuticals Eu rope Ltd (TEPU), es tab lished in Au gust 2006. TEPU is a wholly-owned sub sid -
iary of Takeda and will lead the over all busi ness ac tiv i ties of Takeda’s six sub sid iar ies in Eu rope (in France,
the UK, It aly, Ger many, Aus tria and Swit zer land) by pro mot ing pan-Eu ro pean strat e gies for the short-,
mid-, and long-term and by sup port ing the man age ment of the sub sid iar ies in the re gion. Takeda stated,
“This ap proach will fur ther en hance and com ple ment our solid busi ness struc tures in Eu rope, to wards the
fur ther growth of Takeda’s business in the region”.
TPNA (Takeda Phar ma ceu ti cal’s North Amer ica), Takeda’s wholly owned US mar ket ing sub sid iary has
com pleted con struc tion of new head quar ters in Il li nois where 800 em ploy ees have re lo cated. Takeda al -
lo cated Yen70 bil lion to ac quire 9.3 mil lion of its own shares over Oc to ber fol low ing the pur chase of 4.5
mil lion for Yen33.6 bil lion dur ing Sep tem ber said to im prove in ves tor re turn but is be ing seen as a de fen -
sive tac tic against pos si ble merger and ac qui si tion ac tiv ity. Takeda’s share ac qui si tion pro gram is said to
rep re sent sig nif i cant spend ing for a com pany with con sid er ation to its R&D spend of Yen170 billion in
fiscal 2006.
Le gal ac tion in sti tuted by Abbott against Takeda (al leg ing that Takeda earned ex ces sive prof its from its
sup ply of lansoprazole to jointly owned TAP Pharmaceuticals) was dis missed in a US court as, ac cord ing
to the share hold ers agree ment, these claims must be raised in Japan.
Takeda is to be come sole mar keter of se lected prod ucts from Aska Pharmaceuticals (formed by merger of
Teikoku Hor mone and Grelan in Oc to ber 2005) in Ja pan from April 1 2006, fol low ing the dis con tinu a tion
of a pre vi ous Aska agree ment with Dainippon Sumitomo. Aska has a num ber of pre scrip tion prod ucts in -
clud ing the H2-blocker Altat (roxatidine) which was launched as a switch-OTC product in 2005.
© 2009 IMS Health In cor po rated or its af fil i ates Page 112